×

DNA drug developer Seawolf launches with $100 million funding, Sanofi deal

By Thomson Reuters Nov 16, 2026 | 4:08 AM

Nov 16 (Reuters) – Seawolf Therapeutics on Monday launched publicly with $100 million in funding and a deal with French drugmaker ​Sanofi worth up to $1.2 billion, as ‌it seeks to develop DNA-based medicines.

• The Series A financing was backed by Versant Ventures, MPM BioImpact and Novartis Venture Fund, with participation from Eli ‌Lilly, ​CRISPR Therapeutics and others

• ⁠San Diego-based Seawolf and ⁠Sanofi will develop treatments for bleeding disorders and other undisclosed conditions

• Seawolf could get milestone payments and royalties

• CEO Elizabeth ​Alcamo told Reuters the agreement includes an upfront payment, though she declined to say ⁠how much

• Seawolf’s technology, ⁠called TRIDENT, uses tiny fat ​particles to carry DNA into the nucleus of ​cells without using viruses

• The company says ‌it can offer longer-lasting effects than RNA medicines and the option of repeat dosing that virus-based gene therapies lack

• The lead ⁠program, which has been tested only in animals, aims to build muscle and reduce fat, and ⁠could be ‌used for obesity, muscle loss and ⁠osteoporosis

• Seawolf expects to pick ​a ‌drug candidate by late 2027 and ​file ⁠to begin human trials by the end of 2028

• But “we’ll probably need to raise some additional capital” to reach that stage, Alcamo said

(Reporting by Kamal Choudhury in Bengaluru; Editing by ​Sahal Muhammed)